J Korean Diabetes.  2018 Mar;19(1):15-22. 10.4093/jkd.2018.19.1.15.

Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association

Affiliations
  • 1On Behalf of the Committee of Clinical Practice Guideline of the Korean Diabetes Association, Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. rheesy@khu.ac.kr

Abstract

When starting initial medication in people with type 2 diabetes mellitus (T2DM), the appropriate drug should be selected considering characteristics of the patient, efficacy, side effects, and cost. It is generally recommended to use metformin as the first-line treatment oral hypoglycemic agent in T2DM patients. Metformin is recommended as the first treatment because of its excellent glucose lowering effect, relatively mild side effects, long-term safety, low risk of hypoglycemia, and small weight gain. If it is difficult to use metformin as a first-line treatment, appropriate drugs can be selected based on the clinical situation.

Keyword

Diabetes mellitus; type 2; Hypoglycemic agents; Metformin; Practice guideline

MeSH Terms

Diabetes Mellitus
Diabetes Mellitus, Type 2*
Glucose
Humans
Hypoglycemia
Hypoglycemic Agents
Metformin
Weight Gain
Glucose
Hypoglycemic Agents
Metformin
Full Text Links
  • JKD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error